



MetrioPharm announces regulatory approval to initiate clinical development of MP1032

Zurich, April 7, 2015.

MetrioPharm AG has received approval to commence its phase 1 clinical trial with MP1032 from the German regulatory authority (BfArM). The study will start in April with the enrollment of the first cohort. Its aim is to evaluate the safety and tolerability of orally administered MP1032 in healthy volunteers. The study is conducted in a clinical trial site in Germany.

“The confirmation of safety and tolerability in humans will be an important validation of our good pre-clinical results and an important milestone in the development of our lead compound” commented Dr. Wolfgang Brysch, Chairman of the Board of MetrioPharm AG.

About MP1032

The drug candidate MP1032 is a synthetic small-molecule drug with strong anti-inflammatory properties and an excellent pre-clinical safety profile. MP1032 acts primarily through the modulation of macrophages, the main cells of the innate immune system. Macrophage modulators represent a new class of effective anti-inflammatory drugs with a very broad spectrum of potential clinical applications.

About MetrioPharm AG

MetrioPharm AG is a Swiss pharmaceutical company headquartered in Zurich. MetrioPharm AG is pioneering a new class of drugs for the treatment of chronic inflammatory diseases such as psoriasis, rheumatoid arthritis, or arthritis. The company’s macrophage modulatory compound class is characterized by its broad anti-inflammatory efficacy and good tolerability. .

www.metriopharm.de

Copyright © 2016 MetrioPharm AG, All rights reserved.

MetrioPharm AG Newsletter

Our mailing address is:

MetrioPharm AG

Bleicherweg 45, Zürich

Zürich 8002

Switzerland